QuidelOrtho (QDEL) Scheduled to Post Quarterly Earnings on Thursday

QuidelOrtho (NASDAQ:QDEL) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect QuidelOrtho to post earnings of $0.30 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $637.00 million for the quarter, compared to the consensus estimate of $613.51 million. QuidelOrtho had a positive return on equity of 3.87% and a negative net margin of 65.60%. The firm’s revenue for the quarter was down 4.2% compared to the same quarter last year. During the same period last year, the firm earned $0.26 EPS. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

QuidelOrtho Price Performance

Shares of QDEL opened at $38.99 on Thursday. The business’s 50-day moving average is $42.93 and its two-hundred day moving average is $40.46. The company has a market capitalization of $2.62 billion, a P/E ratio of -1.40 and a beta of 0.09. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.79 and a current ratio of 1.44. QuidelOrtho has a fifty-two week low of $29.74 and a fifty-two week high of $75.86.

Analyst Upgrades and Downgrades

QDEL has been the topic of several analyst reports. UBS Group initiated coverage on QuidelOrtho in a research report on Thursday, September 19th. They set a “neutral” rating and a $50.00 price target on the stock. Craig Hallum raised QuidelOrtho from a “hold” rating to a “buy” rating and increased their price target for the stock from $40.00 to $57.00 in a research report on Thursday, September 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price target on shares of QuidelOrtho in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, QuidelOrtho currently has an average rating of “Hold” and an average target price of $58.83.

Insider Activity

In other news, major shareholder Carlyle Group Inc. sold 78,180 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.94, for a total transaction of $3,122,509.20. Following the sale, the insider now directly owns 8,441,022 shares in the company, valued at $337,134,418.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 365,819 shares of company stock worth $15,027,674 in the last ninety days. Company insiders own 1.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.